A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
NCT ID: NCT06192108
Last Updated: 2025-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
962 participants
INTERVENTIONAL
2024-01-10
2025-09-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06045221
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
NCT06109311
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
NCT06010004
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
NCT05803421
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
NCT01794143
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Orforglipron Dose 1
Participants will receive orforglipron orally.
Orforglipron
Administered orally
Orforglipron Dose 2
Participants will receive orforglipron orally.
Orforglipron
Administered orally
Orforglipron Dose 3
Participants will receive orforglipron orally.
Orforglipron
Administered orally
Dapagliflozin
Participants will receive dapagliflozin orally.
Dapagliflozin
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orforglipron
Administered orally
Dapagliflozin
Administered orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.
* Have been on stable diabetes treatment with metformin ≥1500 milligram per day (mg/day) during the 90 days prior to screening and maintained through randomization.
* Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
* Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.
Exclusion Criteria
* Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
* Have an estimated glomerular filtration rate (eGFR) \<45 milliliter per minute (mL/min)/1.73 square meter (m2)
* Have acute or chronic hepatitis
* Have had chronic or acute pancreatitis any time.
* Have been treated with any antihyperglycemic medication (other than metformin) within the 90 days prior to screening.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alliance Research Institute - Canoga Park
Canoga Park, California, United States
Ark Clinical Research
Long Beach, California, United States
Collaborative Neuroscience Research, LLC
Los Alamitos, California, United States
Wolverine Clinical Trials
Santa Ana, California, United States
CMR of Greater New Haven, LLC
Hamden, Connecticut, United States
Institute of Endocrinology Diabetes, Health & Hormone
Stockbridge, Georgia, United States
Elite Clinical Trials
Rexburg, Idaho, United States
Accellacare - DuPage
Lombard, Illinois, United States
Tandem Clinical Research
Marrero, Louisiana, United States
St. Vincent Healthcare
Billings, Montana, United States
Albuquerque Clinical Trials, Inc.
Albuquerque, New Mexico, United States
Accellacare - Winston-Salem
Winston-Salem, North Carolina, United States
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, United States
Essential Medical Research
Tulsa, Oklahoma, United States
Accellacare - Mt Pleasant
Mt. Pleasant, South Carolina, United States
Accellacare, US Inc., d/b/a Accellacare of Knoxville
Jefferson City, Tennessee, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
Juno Research
Houston, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
The Second People's Hospital of Hefei
Hefei, Anhui, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, Henan, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Nanjing First Hospital
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Affiliated Hospital of Jiangsu University
Zhenjiang, Jiangsu, China
Jinan Central Hospital
Jinan, Shandong, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
CRS Clinical Research Services Mannheim
Mannheim, Baden-Wurttemberg, Germany
Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz
Lingen, Lower Saxony, Germany
Diabetes- und Stoffwechselpraxis Bochum
Bochum, North Rhine-Westphalia, Germany
Zentrum fur klinische Forschung - Köln
Cologne, North Rhine-Westphalia, Germany
InnoDiab Forschung Gmbh
Essen, North Rhine-Westphalia, Germany
Medizentrum Essen Borbeck
Essen, North Rhine-Westphalia, Germany
Institut für Diabetesforschung GmbH Münster
Münster, North Rhine-Westphalia, Germany
Praxis Dr. Veronika Wenzl-Bauer
Rehlingen, Saarland, Germany
Zentrum für klinische Studien
Saint Ingbert, Saarland, Germany
RED-Institut GmbH
Oldenburg in Holstein, Schleswig-Holstein, Germany
Diabetes Zentrum Wilhelmsburg
Hamburg, , Germany
Grupo Ollin Care
Pachuca, Hidalgo, Mexico
Instituto Jalisciense de Investigacion en Diabetes y Obesidad
Guadalajara, Jalisco, Mexico
Cryptex Investigación Clínica S.A. de C.V.
Cuauhtémoc, Ciudad de México, Mexico City, Mexico
ProcliniQ Investigación Clínica SA de CV
Mexico City, Mexico City, Mexico
Instituto de Diabetes, Obesidad y Nutricion
Cuernavaca, Morelos, Mexico
Cardiolink Clin Trials
Monterrey, Nuevo León, Mexico
Clínica García Flores SC
Monterrey, Nuevo León, Mexico
Servicios Integrales Nova de Monterrey S.A. de C.V.
San Nicolás de los Garza, Nuevo León, Mexico
Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.
Culiacán, Sinaloa, Mexico
Consultorio de Medicina Especilizada del Sector Privado
Xalapa, Veracruz, Mexico
Hospital Angeles Xalapa
Xalapa, Veracruz, Mexico
Fundación Cardiovascular de Aguascalientes A.C.
Aguascalientes, , Mexico
Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia
Durango, , Mexico
NZOZ Centrum Medyczne KERmed
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET
Krakow, Lesser Poland Voivodeship, Poland
Centrum Badań Klinicznych Piotr Napora lekarze sp.p.
Wroclaw, Lower Silesian Voivodeship, Poland
Clinical Best Solutions
Lublin, Lublin Voivodeship, Poland
CenterMed Lublin NZOZ
Lublin, Lublin Voivodeship, Poland
Ekamed
Lublin, Lublin Voivodeship, Poland
Centrum Medyczne "Diabetika"
Radom, Masovian Voivodeship, Poland
Zdrowie Osteo-Medic
Bialystok, Podlaskie Voivodeship, Poland
Specderm Poznanska
Bialystok, Podlaskie Voivodeship, Poland
Samodzielny Publiczny Szpital Kliniczny nr 1 SUM
Zabrze, Silesian Voivodeship, Poland
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz, Łódź Voivodeship, Poland
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
Kaohsiung Veterans General Hospital
Kaohsiung City, , Taiwan
Fu Jen Catholic University Hospital
New Taipei City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J2A-MC-GZGV
Identifier Type: OTHER
Identifier Source: secondary_id
2023-507206-13-00
Identifier Type: OTHER
Identifier Source: secondary_id
U1111-1296-1507
Identifier Type: OTHER
Identifier Source: secondary_id
18566
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.